Background: When a passenger suffers an in-flight stroke (IFS), the pilot decides when to expedite access to ground care. Pilot pro-activeness towards IFS could improve outcome and should be promoted. Unfortunately, little is known about a pilot’s stroke pro-activeness or limiting factors. Methods: Randomized controlled trial of an educational intervention (American Stroke Association, 30-slide stroke awareness lecture) through an internet-based computer system using pilot students and instructors as subjects. Pilots completed pre-intervention and post-intervention tests of 25 simulated in-flight scenarios that describe strokes and other neurological and medical symptoms. Outcomes chosen were the percentage of pilots that would use a medical radio service, declare an emergency on board, or divert to the nearest airport for each scenario. Results: Participant pilots (n = 104) were less likely to respond to IFS than to myocardial infarction (p < 0.001). Fear of retaliation by an employer was the most important modifiable limitation. The educational program increased the simulated rate of emergency declarations for in-flight vertebrobasilar strokes (p < 0.001) and subarachnoid hemorrhage (p < 0.001). Conclusions: Pilot-simulated response to certain IFS improves immediately after this educational intervention, which should be disseminated in schools and airlines. Further studies are needed to determine the long-term benefits of this intervention and the impact on actual diversion rates. Companies should also review their policies to shield pilots from retaliation when altering the flight plan for patients.

1.
Sirven JI, Claypool DW, Sahs KL, et al: Is there a neurologist on this flight? Neurology 2002;58:1739–1744.
2.
Goodwin T: In-flight medical emergencies: An overview. BMJ 2000;321:1338–1341.
3.
Lewis MJ, Greenwood RJ, Brew S, Jager HR: Economy class stroke syndromes: Vertebral artery dissection revisited. J Neurol Neurosurg Psychiatry 2003;74:1594–1595.
4.
Goldberg CR, Hirschfeld A: Hemorrhage within brain tumors in association with long air travel. Acta Neurochir (Wien) 2002;144:289–293.
5.
Shesser R: Medical aspects of commercial air travel. Am J Emerg Med 1989;7:216–226.
6.
Pfausler B, Vollert H, Bosch S, Schmutzhard E: Cerebral venous thrombosis: A new diagnosis in travel medicine? J Travel Med 1996;3:165–167.
7.
Hughes RJ, Hopkins RJ, Hill S, et al: Frequency of venous thromboembolism in low to moderate risk long distance air travellers: The New Zealand Air Traveller’s Thrombosis (NZATT) study. Lancet 2003;362:2039–2044.
8.
Lapostolle F, Borron SW, Surget V, Sordelet D, Lapandry C, Adnet F: Stroke associated with pulmonary embolism after air travel. Neurology 2003;60:1983–1985.
9.
Lyznicki JM, Williams MA, Deitchman SD, Howe JP 3rd, Council on Scientific Affairs, American Medical Association: Inflight medical emergencies. Aviat Space Environ Med 2000;71:832–838.
10.
Chan SB, Hogan TM, Silva JC: Medical emergencies at a major international airport: In-flight symptoms and ground-based follow-up. Aviat Space Environ Med 2002;73:1021–1024.
11.
Delaune EF 3rd, Lucas RH, Illig P: In-flight medical events and aircraft diversions: One airline’s experience. Aviat Space Environ Med 2003;74:62–68.
12.
US Department of Transportation: Nondiscrimination on the Basis of Disability in Air Travel. 14 CFR, Part 382, 2004.
13.
Booth MG, Quasim I, Kinsella J: In-flight medical emergencies: Response of anaesthetists who were passengers on commercial flights. Eur J Anaesthesiol 1999;16:840–841.
14.
Leira EC, Bertrand ME, Hogan RE, et al: Continuous or emergent EEG: Can bedside caregivers recognize epileptiform discharges? Intensive Care Med 2004;30:207–212.
15.
Page RL, Joglar JA, Kowal RC, et al: Use of automated external defibrillators by a U.S. airline. N Engl J Med 2000;343:1210–1216.
16.
Greenlund KJ, Neff LJ, Zheng ZJ, et al: Low public recognition of major stroke symptoms. Am J Prev Med 2003;25:315–319.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.